News | November 01, 2024
AbbVie to acquire Aliada Therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The cognitively operated system is a mother patent invention, first launched in India
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Subscribe To Our Newsletter & Stay Updated
